Physician profile
Murali Krishna
NPI 1518979012
$4,426.96
in general payments reported to CMS, 2019-2025
26 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $105 · 2021: $263 · 2022: $717 · 2023: $926 · 2024: $1,097 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792 · Education: $98.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.68 |
| Education | $98.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,857.68 | 2019-2025 | |
| Pfizer INC. | $344.89 | 2024-2025 | |
| Celgene Corporation | $277.09 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $274.75 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $242.25 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Shire North American Group INC | $200.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.39 | 2021-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $127.11 | 2022-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $124.46 | 2024 | |
| Astellas Pharma US INC | $124.46 | 2023 | |
| Eisai INC. | $120.65 | 2022 | |
| Merck Sharp & Dohme LLC | $108.83 | 2019-2024 | Dificid |
| Genzyme Corporation | $90.87 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.93 | 2019 | |
| Intercept Pharmaceuticals, INC. | $49.47 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.90 | 2021 | |
| Braintree Laboratories, INC. | $38.79 | 2021-2024 | Suflave |
| Medtronic, INC. | $33.86 | 2022-2025 | Interstim |
| Gilead Sciences, INC. | $27.09 | 2020-2021 | |
| Inspire Medical Systems, INC. | $25.03 | 2025 | Inspire |
| Ironwood Pharmaceuticals, INC | $23.99 | 2020 | |
| Axsome Therapeutics, INC. | $20.72 | 2023 | Sunosi |
| Mylan Specialty L.P. | $20.36 | 2021 | |
| Ardelyx, INC. | $16.59 | 2024 | Ibsrela |
| Allergan, INC. | $14.44 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murali Krishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.